Federal Register / Vol. 80, No. 20 / Friday, January 30, 2015 / Notices 5115 

project period and one retrospective 

data collection during the first year of 

the three-year project period. The 

retrospective data collection will 

provide information about clients’ 

baseline characteristics prior to 

participation in the model program 

which is needed to compare outcomes 

before and after program 

implementation. Minor formatting 

revisions are requested to the previously 

approved data collection forms. Lastly, 

CDC newly requests approval to 

conduct key informant interviews with 

program clinic and pharmacy staff in 

order to evaluate the program processes 

and to collect time and cost data which 

will be used to estimate the cost of the 

model program. The key informant 

interviews and time and cost data are 

additional data collections from the 

original OMB approval. 

Pharmacy, laboratory and medical 

data will be collected through 

abstraction of all participant clients’ 

pharmacy and medical records. 

Pharmacy, laboratory and medical data 

are needed to monitor retention in care, 

adherence to therapy, viral load 

suppression and other health outcomes. 

Program specific data, such as the 

number of MTM elements completed 

per project site and time spent on 

program activities, will be collected by 

program. Qualitative data will be 

gathered from program staff through inperson or telephone interviews. 

The data collection will allow CDC to 

conduct continuous program 

performance monitoring which includes 

identification of barriers to program 

implementation, solutions to those 

barriers, and documentation of client 

health outcomes. Performance 

monitoring will allow the model 

program to be adjusted, as needed, in 

order to develop a final implementation 

model that is self-sustaining and which 

can be used to establish similar 

collaborations in a variety of clinical 

settings. Collection of cost data will 

allow for the cost of the program to be 

estimated. 

There is no cost to participants other 

than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

(in hours) 

Clinic Data Manager ...... Project clinic characteristics form ........................ 10 3 30/60 15 

Pharmacist ..................... Project pharmacy characteristics form ................ 10 3 30/60 15 

Clinic Data Manager ...... Patient Demographic Information form ............... 10 100 5/60 83 

Clinic Data Manager ...... Initial patient information form ............................. 10 100 1 1,000 

Clinic Data Manager ...... Quarterly patient information form ....................... 10 400 30/60 2,000 

Pharmacist ..................... Pharmacy record abstraction form ...................... 10 400 30/60 2,000 

Key informants ............... Interviewer data collection worksheet ................. 60 2 30/60 60 

Clinic staff ...................... Clinic cost form .................................................... 20 2 10 400 

Pharmacy staff ............... Pharmacy cost form ............................................ 20 2 10 400 

Total ........................ .............................................................................. ........................ ........................ ........................ 5,973 

Leroy A. Richardson, 

Chief, Information Collection Review Office, 

Office of Scientific Integrity, Office of the 

Associate Director for Science, Office of the 

Director, Centers for Disease Control and 

Prevention. 

[FR Doc. 2015–01698 Filed 1–29–15; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Committee on Immunization 

Practices: Notice of Charter 

Amendment 

This gives notice under the Federal 

Advisory Committee Act (Pub. L. 92– 

463) of October 6, 1972, that the 

Advisory Committee on Immunization 

Practices, Centers for Disease Control 

and Prevention (CDC), Department of 

Health and Human Services (HHS), has 

amended their charter to reflect the 

change in the filing date. The amended 

filing date is January 13, 2015. 

For information, contact Dr. Larry 

Pickering, Designated Federal Officer, 

Advisory Committee on Immunization 

Practices, HHS, CDC, 1600 Clifton Road 

NE., Mailstop E05, Atlanta, Georgia 

30333, telephone (404) 639–8562 or fax 

(404) 639–8626. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2015–01767 Filed 1–29–15; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Committee to the Director 

(ACD), Centers for Disease Control and 

Prevention—Health Disparities 

Subcommittee (HDS) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the following meeting of the 

aforementioned subcommittee: 

Time and Date: 11:00 a.m.–12:30 p.m. EST, 

February 26, 2015. 

Place: This meeting will be held by 

teleconference. 

Status: This meeting is open to the public, 

limited only by the availability of telephone 

ports. The public is welcome to participate 

during the public comment, which is 

tentatively scheduled from 12:15 to 12:30 

p.m. To participate in the teleconference, 

please dial (866) 763–0273 Passcode: 

6158968. 

Purpose: The Subcommittee will provide 

advice to the CDC Director through the ACD 

on strategic and other health disparities and 


asabaliauskas on DSK5VPTVN1PROD with NOTICES
5116 Federal Register / Vol. 80, No. 20 / Friday, January 30, 2015 / Notices 

health equity issues and provide guidance on 

opportunities for CDC. 

Matters for Discussion: The Health 

Disparities Subcommittee members will 

discuss progress toward implementation of 

the Health Disparities Subcommittee 

recommendations and discussion of the 

Healthy People 2020 progress review on 

social determinants of health and LGBT 

health. 

The agenda is subject to change as 

priorities dictate. 

Contact Person for More Information: 

Leandris Liburd, Ph.D., M.P.H., M.A., 

Designated Federal Officer, Health 

Disparities Subcommittee, Advisory 

Committee to the Director, CDC, 1600 Clifton 

Road NE., M/S K–77, Atlanta, Georgia 30333 

Telephone (770) 488–8343, Email: LEL1@

cdc.gov. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention (CDC). 

[FR Doc. 2015–01766 Filed 1–29–15; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Initial Review 

The meeting announced below 

concerns Occupational Safety and 

Health Education and Research Centers 

(ERC) PAR 10–217, initial review. 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Times and Dates: 

6:00 p.m.–8:00 p.m., February 23, 2015 

(Closed). 

8:00 a.m.–6:00 p.m., February 24, 2015 

(Closed). 

8:00 a.m.–6:00 p.m., February 25, 2015 

(Closed). 

8:00 a.m.–6:00 p.m., February 26, 2015 

(Closed). 

Place: Renaissance Atlanta Midtown Hotel, 

866 West Peachtree Street NW., Atlanta, 

Georgia 30308, Telephone: (678) 412–2400. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c) (4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters for Discussion: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Occupational Safety and Health 

Education and Research Centers (ERC) PAR 

10–217.’’ 

FOR FURTHER INFORMATION CONTACT: 

George Bockosh, M.S., Scientific Review 

Officer, National Institute for 

Occupational Safety and Health 

(NIOSH), CDC, 2400 Century Center 

Parkway NE., 4th Floor, Mailstop E–74, 

Atlanta, Georgia 30345, Telephone: 

(412) 386–6465, GGB0@CDC.GOV and 

Donald Blackman, Ph.D., Scientific 

Review Officer, NIOSH, CDC, 2400 

Century Center Parkway NE., 4th Floor, 

Room 4204, Mailstop E–74, Atlanta, 

Georgia 30345, Telephone: (404) 498– 

6185, DYB7@CDC.GOV. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2015–01817 Filed 1–29–15; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Initial Review 

The meeting announced below 

concerns ‘‘Comprehensive High-Impact 

HIV Prevention Projects for CommunityBased Organizations’’, Funding 

Opportunity Announcement (FOA) 

PS15–1502, initial review. 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Times and Dates: 9:00 a.m.–4:00 p.m. EST, 

Panels 1–7; February 24, 2015 (Closed), 9:00 

a.m.–4:00 p.m. EST, Panels 8–14; February 

25, 2015 (Closed), 9:00 a.m.–4:00 p.m. EST, 

Panels 15–19; February 26, 2015 (Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c)(4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters for Discussion: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Comprehensive High-Impact 

HIV Prevention Projects for CommunityBased Organizations’’ FOA PS15–1502. 

Contact Person for More Information: Lisa 

R. Williams, Public Health Analyst, CDC, 

1600 Clifton Road NE., Mailstop E07, 

Atlanta, Georgia 30333, Telephone: (404) 

639–1877. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2015–01769 Filed 1–29–15; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Advisory Committee on Immunization 

Practices (ACIP) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) announce 

the following meeting of the 

aforementioned committee. 

Times and Dates: 

8:00 a.m.–5:45 p.m., February 25, 2015. 

8:00 a.m.–1:00 p.m., February 26, 2015. 

Place: CDC, Tom Harkin Global 

Communications Center, 1600 Clifton Road 

NE., Building 19, Kent ‘‘Oz’’ Nelson 

Auditorium, Atlanta, Georgia 30333. 

Status: Open to the public, limited only by 

the space available. 

Purpose: The committee is charged with 

advising the Director, CDC, on the 

appropriate use of immunizing agents. In 

addition, under 42 U.S.C. 1396s, the 

committee is mandated to establish and 

periodically review and, as appropriate, 

revise the list of vaccines for administration 

to vaccine-eligible children through the 

Vaccines for Children (VFC) program, along 

with schedules regarding the appropriate 

periodicity, dosage, and contraindications 

applicable to the vaccines. Further, under 

provisions of the Affordable Care Act, at 

section 2713 of the Public Health Service 

Act, immunization recommendations of the 

ACIP that have been adopted by the Director 

of the Centers for Disease Control and 

Prevention must be covered by applicable 

health plans. 

Matters for discussion: The agenda will 

include discussions on: General 

recommendations; meningococcal vaccines; 

human papillomavirus vaccines; influenza; 


asabaliauskas on DSK5VPTVN1PROD with NOTICES